Introduction
Chronic kidney disease (CKD) and acute kidney injury (AKI) are common among patients hospitalized for myocardial infarction (MI). The prevalence of CKD among patients with MI is 30-40% 1 and the incidence of AKI ranges from 15 to 20%. 2, 3 Both CKD and AKI are more frequent among the elderly 4 who are at a higher risk of shortand long-term complications of kidney injury. Multiple studies have demonstrated that even small increases in creatinine are associated with adverse short-and long-term outcomes in patients with MI. 5 The risk of adverse outcomes associated with kidney injury in MI patients is graded, with worsening outcomes seen with increasing severity of baseline CKD and/or AKI. [5] [6] [7] Decreased utilization of evidence-based medications has been cited as a potential contributor to worse outcomes in these patients. Lower utilization of evidence-based medications has been demonstrated in patients with baseline CKD who present with an acute coronary syndrome (ACS). 1, 8 However, knowledge about prescription patterns in patients with an AKI event during an ACS hospitalization is limited. 9 Another limitation of most prior studies has been consideration of the association of CKD and AKI as distinct exposure variables. 1, 6, 8, 10 Knowledge about the potential for a differential impact of AKI on outcomes across differing severity of baseline CKD is currently lacking.
The ACTION Registry V R -GWTG TM registry, given its rich database of clinical and laboratory data, including initial and peak creatinine, as well as detailed information on discharge medications, is well suited for evaluation of the relationship of in-hospital AKI events with processes of care including discharge medication patterns. Linkage with Centres for Medicare and Medicaid (CMS) outcomes data allow examination of the association and interactions of AKI and baseline CKD status with outcomes in patients > _65 years of age with MI.
Methods

Study population
The study included patients enrolled in the ACTION Registry V R -GWTG TM , a large US quality improvement registry that collects data on consecutive hospitalized patients at participating centres with both STsegment elevation MI and non-ST segment elevation MI as confirmed by the presence of positive cardiac biomarkers. Patients with unstable angina (who are biomarker negative) were not included in the ACTION Registry V R -GWTG TM . Patients with a new left bundle branch block or isolated posterior MI were considered to have a STEMI equivalent. Trained hospital personnel from participating centres collect data from the medical record using standardized data definitions, as previously reported. 11, 12 For long-term outcomes, we linked patient records from ACTION Registry-GWTG to CMS Part A inpatient administrative data files. Medicare is the federal health insurance program in the United States for people who are 65 or older, certain younger people with disabilities, and people with End-Stage Renal Disease (permanent kidney failure requiring dialysis or a transplant, sometimes called ESRD). Part A data covers inpatient hospital stays, care in a skilled nursing facility, hospice care, and some home health care. Because patient information is collected in ACTION Registry-GWTG without unique patient identifiers, we used combinations of indirect identifiers (date of birth, sex, hospital identification, date of admission, and date of discharge) and restricted patients to > _65 years of age in the ACTION Registry-GWTG to enable a linkage with the Medicare claims data, as previously described. 13 The linked follow-up data for our analysis were available through 31 December 2012. A total of 138 680 patients aged > _65 years of age were successfully linked to CMS Part A data files. We then excluded patients who were missing initial or peak creatinine values (n = 32 592), underwent coronary artery bypass grafting during the index hospitalization (n = 9335), died during the index hospitalization (n = 6607), were on dialysis (n = 2848), were in cardiogenic shock during the index hospitalization (n = 4568) or presented with cardiac arrest (n = 575). Patients with cardiac arrest and shock were excluded due to their increased risk of developing AKI and significantly worse outcomes. Patients who were transferred to another healthcare facility during the hospitalization (1945) or non-index admissions in ACTION Registry-GWTG (n = 3710) were also excluded. The final study sample consisted of 76 500 patients from 581 hospitals.
Study definitions
Acute kidney injury was assessed based on the difference between the admission and peak serum creatinine measurements using the modified Acute Kidney Injury Network (AKIN) definition. 3, 14 Mild, moderate, and severe AKI were defined as changes in creatinine from baseline to peak of 0.3 to <0.5, 0.5 to <1.0, and > _1.0 mg/dL, respectively. Chronic kidney disease was defined using the Kidney Disease Outcome Quality Initiative criteria based on admission glomerular filtration rate (GFR) estimated using 
Study outcomes
The primary outcome of the study was 1-year all-cause mortality. 
Statistical analysis
Patients were stratified based on no, mild, moderate, and severe AKI. Patient characteristics at the time of hospitalization were presented using median and interquartile range and compared across ordinal AKI categories using rank correlation tests for continuous variables. Categorical variables were summarized using percentage and compared using group means score tests.
To determine the association of AKI with discharge medication use among eligible patients, generalized logistic estimating equations (GEE) were used to account for clustering of patients within enrolling sites. Adjustment was performed using variables from the ACTION in-hospital mortality model, 16 including age, sex, race, heart failure, heart rate, systolic blood pressure, electrocardiogram (ECG) findings (STEMI, STsegment changes, vs. no ST-segment changes), current/recent smoking, hypertension, dyslipidaemia, diabetes mellitus, chronic lung disease, peripheral arterial disease, prior MI, prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting, prior heart failure, prior stroke, baselin troponin ratio (relative to upper limit of normal), and baseline haematocrit. In addition to the variables in the mortality model, baseline CKD was also included. Hospital level analyses were performed examining patterns of prescriptions of ACEI or ARB. The proportion of patients with AKI receiving a discharge prescription for ACEI or ARB prescription on discharge was estimated for each hospital using a generalized linear mixed model with hospital as random effect.
The cumulative incidence of long-term outcomes (mortality, ARF, and readmission) was estimated and compared across AKI categories using the log-rank test (mortality) and Gray test (ARF, readmission). Survival analyses were performed using Cox proportional hazards regression models with robust standard errors to account for clustering of patients within the same hospital. The covariates used for adjustment were adapted from the CRUSADE long-term mortality model which consisted of age, sex, race, weight, dyslipidaemia, initial haematocrit, initial troponin ratio, prior stroke, diabetes mellitus, signs of heart failure, initial systolic blood pressure, initial heart rate, prior PCI, electrocardiographic changes (STEMI, ST depression or transient ST elevation, T-wave inversion, vs. none), hypertension, prior coronary artery bypass graft, prior congestive heart failure (CHF), prior peripheral arterial disease, current/recent smoker, and prior MI. 17 Additionally, discharge medications and CKD
were included in the model. Initial creatinine was excluded from the multivariable analysis to avoid collinearity with CKD in the model. Statistical testing for interaction between AKI and CKD was performed by adding a multiplicative interaction term for AKI category x CKD category. Sensitivity analyses were performed restricting the study population to those who underwent cardiac catheterization to minimize the influence of contrast volume on study observations. The percentage of missing values was low, <0.8% for all variables included in the multivariable model. In multivariable modelling, missing values of the continuous variables were imputed to STEMI/NSTEMI and gender-specific medians of the non-missing values and missing values of the categorical variables were imputed to their most common value.
All analyses were performed using SAS software (version 9.3; SAS, Cary, NC, USA) and statistical significance was determined by a twosided P-value < 0.05.
Results
The median age of the study population was 77 years, with 53% male and 88% white. The prevalence of baseline CKD was: Stage 3 (41.2%), Stage 4 (6.7%), and Stage 5 (1.0%). The incidence of AKI was: mild (7.5%), moderate (6.0%), and severe (3.0%).
The baseline and in-hospital characteristics according to categories of AKI are presented in Table 1 . Patients developing AKI had higher prevalence of comorbidities at the time of presentation including hypertension, diabetes mellitus, dyslipidaemia, prior CHF, prior revascularization, atrial fibrillation, prior stroke, and peripheral arterial disease. Patients with AKI had longer median length of stay (5 days for mild, 6 for moderate, and 8 for severe) compared with those with no AKI (3 days). Patients with no AKI had slightly higher rates of cardiac catheterization (80%) compared with patients with mild AKI (70%), moderate AKI (62%), and severe AKI (63%).
Processes of care
No differences in discharge use of aspirin, P2Y12 inhibitors (clopidogrel and prasugrel) and beta-blockers across AKI categories were observed ( Table 2 ). In contrast, small differences in statin use were seen with increasing AKI severity: no AKI (91%), mild (89%), moderate (87%), and severe AKI (86%), P(trend) <0.04. Differences across AKI stage were larger for ACEI/ARB use: no AKI (75%), mild (74%), moderate (67%), and severe AKI (52%), P(trend) <0.001. After adjustment for covariates, lower ACEI/ARB prescription on discharge was seen in patients with moderate AKI [odds ratio (OR): 0.70, 0.64-0.76] and severe AKI (OR: 0.42, 0.37-0.47) compared with those without AKI ( Table 2) . Substantial hospital level variation was observed in the use of ACEI/ARBs at discharge among patients with AKI, with rates ranging from 25% to 95%. In-hospital catheterization was less frequent among patients with AKI, with only small differences seen for cardiac rehabilitation referral and smoking cessation counselling across AKI severity. After multivariable adjustment, moderate AKI remained associated with lower rates of cardiac catheterization. No consistent pattern was observed regarding referral for cardiac rehabilitation or smoking cessation in the multivariableadjusted analyses.
Clinical outcomes
The unadjusted estimated 1-year mortality rate was 15% in patients without AKI, vs. 27%, 35%, and 44% in patients experiencing mild, moderate, and severe AKI, respectively ( Figure 1A ) (log rank P = 0.001). A similar graded association was observed across AKI categories for the secondary outcomes of readmission for ARF ( Figure 1B ) and all-cause readmission ( Figure 1C) .
A significant interaction was observed between AKI and CKD categories for the outcomes of all-cause mortality, acute renal failure, and all-cause readmission (P interaction <0.001 for each). Thus, multivariable analyses evaluating the association of AKI with clinical outcomes were stratified by baseline CKD status. Among patients with no or mild to moderate CKD, robust and graded associations with 1-year mortality were observed across increasing AKI categories; in contrast, among patients with Stage 5 CKD, no association between increasing AKI categories and mortality was observed (Figure 2A) . Similar associations were observed for 1-year ARF ( Figure 2B ) and 1-year readmission ( Figure 2C) . Sensitivity analyses restricting the study population to patients undergoing cardiac catheterization demonstrated similar results regarding associations of AKI with discharge medication and with all endpoints (data not shown).
Discussion
In a large cohort of elderly patients with acute MI, 1-year mortality, renal failure, and hospital readmission worsened with increasing severity of AKI, with even small increases in creatinine associated with worse outcomes. This association persisted after adjustment for clinical variables commonly associated with long-term mortality after MI, including discharge medication use, and was modified by the presence of baseline CKD, with attenuation of these associations across increasing severity of baseline CKD. Further, moderate to severe AKI was associated with a substantial decrease in discharge ACEI/ARB use. Hospital level analysis demonstrated marked variation in discharge ACE/ARB use among patients with ACS and AKI, suggesting that local practice patterns, rather than patient characteristics, largely drove the decision to withhold ACE/ARB therapy after an AKI event.
Lower rates of ACEI/ARB use did not appear to explain worsened outcomes associated with AKI, as adjustment for discharge medications did not attenuate the associations of AKI with outcomes.
Although prior studies have demonstrated lower rates of evidence-based medication use at discharge among AMI patients with advancing stages of CKD, knowledge about discharge prescription 1 Wetmore et al. 9 demonstrated decreased rates of ACEI/ARB prescriptions in 7000 AMI patients with advancing CKD stages and with incident AKI. However, that study was limited by lack of grading of AKI severity and of assessment of long-term outcomes associated with decreased ACEI/ARB prescription. Interestingly, our study demonstrated that AKI, irrespective of severity, did not seem to affect the prescription of most evidence-based medications at discharge. We observed small differences in statin use and larger differences in ACEI/ARB use with worsening AKI. Additionally, it was encouraging to note that mild elevations in creatinine (0.3 to <0.5 mg/dL) did not dissuade most physicians from prescribing ACEI/ARB at discharge. In contrast, moderate (0.5 to <1.0 mg/dL) and severe (> _1.0 mg/dL) creatinine elevations were associated with a significant decrease in ACEI/ARB prescription at discharge. This observation could be attributed to the absence of clear guidelines delineating specific thresholds for withholding ACEI/ARB in the setting of AKI, as well as concerns about an increased risk of developing hyperkalaemia in the setting of decreased renal function. The ambiguity in this area is highlighted by the large variation in use of ACE/ARB for patients with AKI among hospitals in our registry. Acute kidney injury has been associated with worse long-term outcomes in several previous studies of patients with ACS, with even small elevations in creatinine associated with increased risk. 7, 10, 18 However, these studies are notable for a number of limitations including a less contemporary time frame, as reflected by low rates of cardiac catheterization, 7 inclusion of patients without ACS, 10 lack of inclusion of meaningful clinical outcomes beyond mortality, 7 small study size, 9 and absence of data on AKI severity. 9,10 These limitations could affect the generalizability of prior studies to the broad population of AMI patients. Strengths of our study include the collection of granular data regarding use of evidence-based medication use at discharge in patients without any documented contraindication to use, inclusion of a large and representative population, and collection of multiple meaningful clinical outcomes. The persistent association of AKI with poorer long-term outcomes across a spectrum of AKI severity, the relatively stable pattern of discharge use of most medications and the absence of attenuation of long-term risk of AKI after adjustment for discharge medications, suggest a distinct mechanism through which AKI is associated with worse outcomes beyond lower use of discharge medications. The effect of AKI on long-term outcomes was notably modified by baseline CKD. This has been examined in prior studies, and the . ................................................................................................ ..... Adjusted for age, sex, race, heart failure, heart rate, systolic blood pressure, ECG findings (STEMI, ST-segment changes, vs. no ST-segment changes), current/ recent smoking, hypertension, dyslipidaemia, diabetes mellitus, chronic lung disease, peripheral arterial disease, prior MI, prior percutaneous coronary intervention, prior coronary artery bypass grafting, prior heart failure, prior stroke, troponins, haematocrit, and baseline CKD. 
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This discordance is likely secondary to the limited power (393 events) in the study by Amin et al. 18 to detect an interaction compared with our study (>12 000 events) or the study by Parikh et al.,
7
(>10 000 events). The attenuated effect of AKI on long-term outcomes in patients with advanced baseline CKD is unsurprising given the already high-competing risk of adverse cardiovascular outcomes conferred by CKD. More importantly, these data clearly demonstrate that among patients with normal or near normal baseline renal function, the development of even mild AKI after AMI is associated with substantially higher risk of adverse outcomes. The nephrotoxic effects of contrast material used during angiography are frequently implicated as the culprit for development of AKI in patients presenting with ACS. However, the pathophysiology leading to the development of AKI in patients with MI is complex. 19 Type 1 cardio renal syndrome, i.e. acute cardiac dysfunction leading to decreased cardiac output and increased venous congestion that combine to cause acute injury to the kidneys in absence of exposure to contrast, is increasingly appreciated as an important cause of AKI. 20 In our study, patients with AKI more commonly had history or symptoms of heart failure, which could lead to increased use of diuretic agents and subsequent AKI from diuretic use. It is unclear if the long-term risks associated with AKI differs based on the aetiology of renal injury, a question that should be explored in future studies. Our study has several limitations. First, the findings are susceptible to residual confounding in spite of our adjustment for multiple demographic and clinical variables. Second, half of the patients from the ACTION Registry V R -GWTG TM were excluded from the final study population with majority of the patients being excluded for missing creatinine values (32 592), underwent CABG (9335) and had cardiogenic shock (4568). However, our large study population was still in excess of 75 000 patients. Third, the initial serum creatinine in our study was obtained on admission. Hence, we were unable to detect an AKI event if the increase in creatinine started prior to presentation. This could lead to underestimation of the frequency and severity of AKI but would bias the study results towards the null. Fourth, we accounted for medications at discharge but did not have information on continued outpatient use. However, the resultant misclassification would not be likely to affect our study estimates since adjustment for discharge medications did not change the parameter estimates associated with AKI categories in our study. Fifth, the median age of our study population is in the 70s and thus the study results may not be generalizable to a younger patient population. Sixth, we did not include residual LV function in our multivariable model, which is an important predictor of AKI, due to incomplete capture of echocardiographic variables. However, we did adjust for the degree of troponin elevation, which is a measure of infarct size and directly related to residual LV function. Sixth, use of a high sensitivity troponin assay (instead of standard troponin assay) would have affected patient selection. However, high sensitivity assays are not available for use in the USA at this time. Finally, ours is an observational study and Figure 1 Cumulative incidence of 1-year mortality (A), acute renal failure (B), and all cause readmission (C) after discharge, stratified by incidence and severity of AKI. Mild, moderate, and severe AKI were defined as changes in creatinine from baseline to peak of 0.3 to < 0.5, 0.5 to < 1.0, and > _ 1.0 mg/dL, respectively. ARF, acute renal failure.
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we are unable to comment on the causality between AKI and longterm outcomes. Rather, an AKI event appears to be a marker of higher risk and potentially identifies patients who may require more aggressive care.
Conclusion
In a large, national registry we demonstrate that AKI is associated with worse long-term mortality, renal failure, and all cause Figure 2 Multivariable adjusted hazard ratios for 1-year mortality (A), acute renal failure (B), and all cause hospitalization (C), stratified by AKI categories and by baseline CKD stage. 17 Variables used for adjustment include age, sex, race, heart failure, heart rate, systolic blood pressure, ECG findings (STEMI, ST-segment changes, vs. no ST-segment changes), current/recent smoking, hypertension, dyslipidaemia, diabetes mellitus, chronic lung disease, peripheral arterial disease, prior MI, prior percutaneous coronary intervention, prior coronary artery bypass grafting, prior heart failure, prior stroke, troponins, haematocrit, baseline CKD, and discharge medications.
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